[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555000":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":41,"collaborators":44,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":73,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"University of Modena and Reggio Emilia","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with hematologic cancer scheduled to undergo HSCT or CAR T-cell therapy",null,"The participants will be selected at the Hematology Unit of Azienda USL-IRCCS di Reggio Emilia, Northern Italy, two months prior to undergoing transplantation or CAR-T cell treatment. Eligible participants must meet the following inclusion criteria: have hematologic cancer and be scheduled for HSCT or CAR T-cell therapy; be at least 18 years old; able to provide informed consent and actively participate in the study; proficient in understanding and communicating in Italian.\n\nPatients who are unable to perform physical tests or have contraindications to movement will be excluded from the study",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Margherita Schiavi, PhD Candidate","CONTACT","+390522522441","margherita.schiavi@ausl.re.it",[19],{"facility":20,"status":10,"city":21,"state":10,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"AUSL-IRCCS di Reggio Emilia","Reggio Emilia","42122","Italy","IT",{"type":26,"coordinates":27},"Point",[28,29],10.63125,44.69825,{"lat":29,"lon":28},[32,36,39],{"name":33,"role":15,"phone":34,"phoneExt":35,"email":17},"Margherita Schiavi, Phd Candidate","+390522522","441",{"name":37,"role":15,"phone":16,"phoneExt":35,"email":38},"Stefania Costi, PhD, Researcher","stefania.costi@unimore.it",{"name":14,"role":40,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":40,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Stefania Costi","Researcher",[45],{"name":46,"class":47},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV","100555000","rehabilitation-needs-for-hematologic-cancer-candidate-for-hematopoietic-stem-cell-transplantation-or-car-t-cell-therapy-100555000",false,"NCT06506396","Rehabilitation Needs for Hematologic Cancer Candidate for Hematopoietic Stem Cell Transplantation or CAR T-Cell Therapy","Outcomes and Rehabilitation Needs of Patients With Hematologic Cancer Candidate for Hematopoietic Stem Cell Transplantation or CAR T-Cell Therapy: a Prospective Observational Study","HEMATOneeds","Inclusion Criteria:\n\n* Patients with hematologic cancer scheduled to undergo HSCT or CAR T-cell therapy;\n* Age ≥18 years\n* Able to provide informed consent to participate in the study\n* Able to understand and participate in the study\n* Able to understand and communicate in the Italian language\n\nExclusion Criteria:\n\n• Patients who are unable to perform physical tests or have contraindications to movement","ALL","18 Years",{"count":59,"type":60},20,"ESTIMATED","OBSERVATIONAL","Hematopoietic Stem Cell Transplantation (HSCT) and CAR T-cell therapy are effective treatments for blood cancers, extending patients lives. However, these treatments can cause side effects like muscle weakness and fatigue. Recent findings suggest these issues can significantly affect patient quality of life during CAR T-cell therapy.\n\nPatients undergoing HSCT and CAR T-cell therapy often face frequent infections and strong immune responses, requiring long periods of rest. This worsens their physical condition and impacts their quality of life, muscle strength, and fatigue levels. Minimizing these side effects is crucial to improve the well-being of patients undergoing these advanced treatments.\n\nThis study aims to assess the physical abilities (main goal) of patients preparing for HSCT or CAR T-cell therapy. It also aims to examine their quality of life and describe the symptoms and complications they may experience. The results will help identify rehabilitation needs for these patients.",[64,65,66],"Stem Cell Transplantation","Immunotherapy","CAR T-Cell Therapy",[68,69,70,71,72],"Functional Status","Quality of life","Needs Assesment","Physical Conditioning, Human","Hematologic Neoplasms","NOT_YET_RECRUITING","2024-07-17",{"date":76,"type":77},"2024-07-19","ACTUAL",{"date":79,"type":60},"2024-08",{"date":81,"type":60},"2025-05",{"name":5,"class":6},1]